The global Retinal Biologics Market was valued at USD 22.5 billion in 2023 and is expected to reach USD 49.5 billion by 2032, growing at a compound annual growth rate (CAGR) of 9.2% during the forecast period from 2024 to 2032. The market's growth is propelled by the increasing prevalence of retinal disorders, such as age-related macular degeneration (AMD) and diabetic retinopathy, alongside...
English
Arabic
Français
Español
Português
Türkçe
Dutch
Italiano
Russian
Romaian